argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline – GlobeNewswire

Leave a Comment / Mega Deals / By

argenx to buy Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline  GlobeNewswire

Source: news.google.com

Related Posts

Leave a Comment

Your email address will not be published. Required fields are marked *